Published in J Am Soc Nephrol on July 26, 2007
Cardiorenal Risk Stratification Pilot Study (CRiSPS) | NCT03628443
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
The amazing osteocyte. J Bone Miner Res (2011) 5.32
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Epidemiology of chronic kidney disease in children. Pediatr Nephrol (2011) 3.42
Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol (2009) 3.01
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol (2009) 2.81
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol (2011) 2.60
Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol (2011) 2.59
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol (2009) 2.26
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis (2011) 1.83
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Kidney Int (2014) 1.65
Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.65
FGF-23: More than a regulator of renal phosphate handling? J Bone Miner Res (2010) 1.63
Emerging risk factors and markers of chronic kidney disease progression. Nat Rev Nephrol (2009) 1.58
Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23? Nephrol Dial Transplant (2011) 1.57
Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int (2012) 1.57
Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J Invest Dermatol (2009) 1.51
Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease. J Am Soc Nephrol (2011) 1.42
Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res (2012) 1.41
Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 1.37
Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol (2011) 1.36
Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol (2009) 1.30
Bone turnover markers: use in osteoporosis. Nat Rev Rheumatol (2012) 1.25
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol (2010) 1.21
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One (2012) 1.20
Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol (2011) 1.20
Phosphate and FGF-23. Kidney Int Suppl (2011) 1.19
Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res (2013) 1.17
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol (2013) 1.10
FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol (2012) 1.09
Parathyroid-specific deletion of Klotho unravels a novel calcineurin-dependent FGF23 signaling pathway that regulates PTH secretion. PLoS Genet (2013) 1.09
Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol (2008) 1.07
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Dietary Sources of Phosphorus among Adults in the United States: Results from NHANES 2001-2014. Nutrients (2017) 1.07
Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol (2013) 1.05
Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol (2011) 1.05
Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One (2011) 1.05
The use of targeted biomarkers for chronic kidney disease. Adv Chronic Kidney Dis (2010) 1.05
Trefoil factor 3 predicts incident chronic kidney disease: a case-control study nested within the Atherosclerosis Risk in Communities (ARIC) study. Am J Nephrol (2011) 1.03
Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol (2008) 1.03
The role of FGF23 in CKD--with or without Klotho. Nat Rev Nephrol (2012) 1.02
Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol (2011) 1.02
Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol (2014) 1.01
Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens (2012) 1.01
FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol (2012) 1.01
Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis (2013) 0.98
Serum fibroblast growth factor-23 is associated with incident kidney disease. J Am Soc Nephrol (2014) 0.97
Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. J Am Soc Nephrol (2014) 0.96
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: an analysis of the MASTERPLAN cohort. BMC Nephrol (2012) 0.95
Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol (2013) 0.93
Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol (2013) 0.92
Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat (2010) 0.90
Role of vitamin D in chronic kidney disease. Semin Nephrol (2009) 0.90
Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study. Atherosclerosis (2014) 0.89
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
FGF-23 in bone biology. Pediatr Nephrol (2009) 0.89
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant (2013) 0.88
Genomic biomarkers for chronic kidney disease. Transl Res (2012) 0.88
Biomarkers of kidney injury and klotho in patients with atherosclerotic renovascular disease. Clin J Am Soc Nephrol (2014) 0.87
Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol (2010) 0.87
The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol (2013) 0.87
The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know. Adv Nutr (2013) 0.87
Calcium regulation and bone mineral metabolism in elderly patients with chronic kidney disease. Nutrients (2013) 0.87
The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86
Homoarginine and progression of chronic kidney disease: results from the Mild to Moderate Kidney Disease Study. PLoS One (2013) 0.86
Novel bone endocrine networks integrating mineral and energy metabolism. Curr Osteoporos Rep (2013) 0.86
Clinical Significance of FGF-23 in Patients with CKD. Int J Nephrol (2011) 0.86
Renal phosphate loss in long-term kidney transplantation. Clin J Am Soc Nephrol (2011) 0.85
Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One (2015) 0.85
Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol (2014) 0.85
A single preoperative FGF23 measurement is a strong predictor of outcome in patients undergoing elective cardiac surgery: a prospective observational study. Crit Care (2015) 0.85
1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int (2012) 0.84
Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab (2011) 0.84
Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol (2014) 0.84
Chronic kidney disease: mineral and bone disorder in children. Semin Nephrol (2013) 0.84
Is fibroblast growth factor 23 a harbinger of mortality in CKD? Pediatr Nephrol (2011) 0.84
FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem (2014) 0.83
The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol (2012) 0.83
Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease. PLoS One (2013) 0.83
Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens (2009) 0.82
Biomarkers in chronic kidney disease, from kidney function to kidney damage. World J Nephrol (2015) 0.82
Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrol (2013) 0.82
Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011) (2013) 0.82
Mineral metabolism and outcomes in chronic kidney disease stage 2-4 patients. BMC Nephrol (2013) 0.81
Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One (2013) 0.81
Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett (2016) 0.81
The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract (2013) 0.81
Association of relative telomere length with progression of chronic kidney disease in two cohorts: effect modification by smoking and diabetes. Sci Rep (2015) 0.81
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med (2011) 11.11
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet (2010) 7.69
Nephron number in patients with primary hypertension. N Engl J Med (2003) 6.74
Chronic kidney disease: effects on the cardiovascular system. Circulation (2007) 6.19
Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med (2007) 5.82
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet (2008) 5.23
A genome-wide perspective of genetic variation in human metabolism. Nat Genet (2009) 5.00
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet (2008) 4.67
Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol (2009) 4.31
Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med (2010) 3.60
Telomere length and risk of incident cancer and cancer mortality. JAMA (2010) 3.55
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2011) 3.48
On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int (2002) 3.16
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial DNA haplogroups. Hum Mutat (2010) 3.02
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay. Int J Epidemiol (2009) 2.87
Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting. PLoS One (2010) 2.84
Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int (2005) 2.78
Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant (2010) 2.70
CUBN is a gene locus for albuminuria. J Am Soc Nephrol (2011) 2.70
Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet (2011) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Essential hypertension. Lancet (2007) 2.63
Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature (2011) 2.59
Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study. J Am Coll Cardiol (2008) 2.56
Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat Med (2013) 2.55
Prospective evaluation of operating characteristics of prostate cancer detection biomarkers. J Urol (2010) 2.54
Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int (2002) 2.50
Linking health-status measurements to the international classification of functioning, disability and health. J Rehabil Med (2002) 2.48
Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol (2011) 2.40
Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease--a Mendelian Randomisation study. PLoS One (2008) 2.37
A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthritis Rheum (2005) 2.36
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int (2011) 2.34
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ (2013) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Genetic architecture of the APM1 gene and its influence on adiponectin plasma levels and parameters of the metabolic syndrome in 1,727 healthy Caucasians. Diabetes (2006) 2.23
Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol (2003) 2.20
Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation (2006) 2.18
Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol (2009) 2.13
Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range. J Am Coll Cardiol (2010) 2.13
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
[Metformin-associated lactic acidosis with acute renal failure in type 2 diabetes mellitus]. Med Klin (Munich) (2002) 2.03
The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int (2005) 2.02
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
Serum creatinine, cystatin C, and beta-trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem (2010) 1.95
1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol (2003) 1.86
A genome-wide association study of metabolic traits in human urine. Nat Genet (2011) 1.84
Gender-specific association of adiponectin as a predictor of progression of chronic kidney disease: the Mild to Moderate Kidney Disease Study. Kidney Int (2007) 1.83
Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. Circ Cardiovasc Genet (2008) 1.82
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Association of ankle-brachial index and plaques in the carotid and femoral arteries with cardiovascular events and total mortality in a population-based study with 13 years of follow-up. Eur Heart J (2006) 1.82
Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant (2002) 1.81
Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler Thromb Vasc Biol (2010) 1.81
Genetic variation at chromosome 1p13.3 affects sortilin mRNA expression, cellular LDL-uptake and serum LDL levels which translates to the risk of coronary artery disease. Atherosclerosis (2009) 1.80
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals. Atherosclerosis (2009) 1.78
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. JAMA Intern Med (2013) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
Membrane targeting and secretion of mutant uromodulin in familial juvenile hyperuricemic nephropathy. J Am Soc Nephrol (2006) 1.73
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease? Kidney Int (2004) 1.72
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant (2011) 1.71
Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol (2002) 1.70
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet (2012) 1.68
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68
Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection. J Urol (2009) 1.68
Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet (2010) 1.67
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66